Recombinant Mouse Antibody (S67-27) is capable of binding to Kdo (3-deoxy-α-D-manno-oct-2-ulosonic acid), expressed in Chinese Hamster Ovary cells (CHO). MAb S67-27 is a remarkable near-germline antibody that displays higher affinity for a synthetic, nonnatural ligand than for its cognate immunogen, or other structurally related naturally occurring antigens. It was raised by immunization of naive mice with a Ko(2→4)Kdo disaccharide glycoconjugate; however, it does not react specifically with Ko or Ko(2→4)Kdo, but rather binds with equal affinity to several distinct Kdo oligosaccharides.
Figure 1 Binding curves of monoclonal antibodies A20 (left column), and S67-27 (right column) against Kdo-BSA.
ELISA plates were coated with 400 (filled circles), 200 (filled triangles), 100 (filled squares) 50 (filled diamonds), 25 (open circles), 12.5 (open triangles), 6.3 (open squares) and 3.2 (open diamonds) pmol of ligand per ml of Kdo-BSA (A) and reacted with antibody concentrations (ng/ml) as indicated on the abscissa. OD405 values are the mean of quadruplicates with confidence values not exceeding 10%. (Kdo: 3-deoxy-α-D-manno-oct-2-ulosonic acid, Ko: D-glycero-α-D-talo-oct-2-ulosonic acid)
Brade, L., Gronow, S., Wimmer, N., Kosma, P., & Brade, H. (2002). Monoclonal antibodies against 3-deoxy-α-D-manno-oct-2-ulosonic acid (Kdo) and D-glycero-α-D-talo-oct-2-ulosonic acid (Ko). Journal of Endotoxin Research, 8(5), 357-364.
Figure 2 Binding curves of monoclonal antibodies A20 (left column), and S67-27 (right column) against Ko-BSA.
ELISA plates were coated with 400 (filled circles), 200 (filled triangles), 100 (filled squares) 50 (filled diamonds), 25 (open circles), 12.5 (open triangles), 6.3 (open squares) and 3.2 (open diamonds) pmol of ligand per ml of Ko-BSA (B) and reacted with antibody concentrations (ng/ml) as indicated on the abscissa. OD405 values are the mean of quadruplicates with confidence values not exceeding 10%. (Kdo: 3-deoxy-α-D-manno-oct-2-ulosonic acid, Ko: D-glycero-α-D-talo-oct-2-ulosonic acid)
Brade, L., Gronow, S., Wimmer, N., Kosma, P., & Brade, H. (2002). Monoclonal antibodies against 3-deoxy-α-D-manno-oct-2-ulosonic acid (Kdo) and D-glycero-α-D-talo-oct-2-ulosonic acid (Ko). Journal of Endotoxin Research, 8(5), 357-364.
Figure 3 Binding curves of monoclonal antibodies A20 (left column), and S67-27 (right column) against Ko(2→4)Kdo-BSA.
ELISA plates were coated with 400 (filled circles), 200 (filled triangles), 100 (filled squares) 50 (filled diamonds), 25 (open circles), 12.5 (open triangles), 6.3 (open squares) and 3.2 (open diamonds) pmol of ligand per ml of Ko(2→4)Kdo-BSA (C) and reacted with antibody concentrations (ng/ml) as indicated on the abscissa. OD405 values are the mean of quadruplicates with confidence values not exceeding 10%. (Kdo: 3-deoxy-α-D-manno-oct-2-ulosonic acid, Ko: D-glycero-α-D-talo-oct-2-ulosonic acid)
Brade, L., Gronow, S., Wimmer, N., Kosma, P., & Brade, H. (2002). Monoclonal antibodies against 3-deoxy-α-D-manno-oct-2-ulosonic acid (Kdo) and D-glycero-α-D-talo-oct-2-ulosonic acid (Ko). Journal of Endotoxin Research, 8(5), 357-364.
Figure 4 Binding curves of monoclonal antibodies A20 (left column), and S67-27 (right column) against Kdo(2→4)Ko-BSA.
ELISA plates were coated with 400 (filled circles), 200 (filled triangles), 100 (filled squares) 50 (filled diamonds), 25 (open circles), 12.5 (open triangles), 6.3 (open squares) and 3.2 (open diamonds) pmol of ligand per ml of Kdo(2→4)Ko-BSA (D) and reacted with antibody concentrations (ng/ml) as indicated on the abscissa. OD405 values are the mean of quadruplicates with confidence values not exceeding 10%. (Kdo: 3-deoxy-α-D-manno-oct-2-ulosonic acid, Ko: D-glycero-α-D-talo-oct-2-ulosonic acid)
Brade, L., Gronow, S., Wimmer, N., Kosma, P., & Brade, H. (2002). Monoclonal antibodies against 3-deoxy-α-D-manno-oct-2-ulosonic acid (Kdo) and D-glycero-α-D-talo-oct-2-ulosonic acid (Ko). Journal of Endotoxin Research, 8(5), 357-364.
Figure 5 Binding curves of monoclonal antibodies A20 (left column), and S67-27 (right column) against Kdo(2→4)Kdo-BSA.
ELISA plates were coated with 400 (filled circles), 200 (filled triangles), 100 (filled squares) 50 (filled diamonds), 25 (open circles), 12.5 (open triangles), 6.3 (open squares) and 3.2 (open diamonds) pmol of ligand per ml of Kdo(2→4)Kdo-BSA (E) and reacted with antibody concentrations (ng/ml) as indicated on the abscissa. OD405 values are the mean of quadruplicates with confidence values not exceeding 10%. (Kdo: 3-deoxy-α-D-manno-oct-2-ulosonic acid, Ko: D-glycero-α-D-talo-oct-2-ulosonic acid)
Brade, L., Gronow, S., Wimmer, N., Kosma, P., & Brade, H. (2002). Monoclonal antibodies against 3-deoxy-α-D-manno-oct-2-ulosonic acid (Kdo) and D-glycero-α-D-talo-oct-2-ulosonic acid (Ko). Journal of Endotoxin Research, 8(5), 357-364.
Figure 6 Surface plasmon resonance of S67-27 binding to Kdo analogs.
Sensorgram overlays for the binding of 12.5, 25, 50, 75, 100, 200, 400, and 800 Nm S67-27 Fab to 980 RUs of immobilized Kdo(2→4)Kdo-BSA, the inset shows equilibrium analysis.
Brooks, C. L., Blackler, R. J., Sixta, G., Kosma, P., Müller-Loennies, S., Brade, L., ... & Evans, S. V. (2010). The role of CDR H3 in antibody recognition of a synthetic analog of a lipopolysaccharide antigen. Glycobiology, 20(2), 138-147.
Figure 7 Surface plasmon resonance of S67-27 binding to Kdo analogs.
10, 20, 40, 80, 160, 320, 640 and 1280 nM S67-27 Fab to 160 RUs of immobilized Kdo(2→8)Kdo(2→4)Kdo-BSA. The open black circles are the data points and the curves the fitting of the data to a 1:1 interaction model.The inset shows equilibrium analysis.
Brooks, C. L., Blackler, R. J., Sixta, G., Kosma, P., Müller-Loennies, S., Brade, L., ... & Evans, S. V. (2010). The role of CDR H3 in antibody recognition of a synthetic analog of a lipopolysaccharide antigen. Glycobiology, 20(2), 138-147.
Figure 8 Surface plasmon resonance of S67-27 binding to Kdo analogs.
Sensorgram overlays for the binding of 5, 10, 20, 40, 60 and 80 nM S67-27 Fab to 570 RUs of immobilized Kdo(2→8)Kdo(2→4)Kdo-BSA, the inset shows linear fitting (lines) and the initial data points (open black circles).
Brooks, C. L., Blackler, R. J., Sixta, G., Kosma, P., Müller-Loennies, S., Brade, L., ... & Evans, S. V. (2010). The role of CDR H3 in antibody recognition of a synthetic analog of a lipopolysaccharide antigen. Glycobiology, 20(2), 138-147.
Figure 9 Surface plasmon resonance of S67-27 binding to Kdo analogs.
Standard curves for S67-26 Fab concentration assay based on the steady state of initial mass transport limited rates from the sensorgrams in Figure 8.
Brooks, C. L., Blackler, R. J., Sixta, G., Kosma, P., Müller-Loennies, S., Brade, L., ... & Evans, S. V. (2010). The role of CDR H3 in antibody recognition of a synthetic analog of a lipopolysaccharide antigen. Glycobiology, 20(2), 138-147.
Figure 10 Surface plasmon resonance of S67-27 binding to Kdo analogs.
The fitting to a solution affinity model of data for the inhibition of (E) S67-27 Fab binding to 570 RUs of immobilized Kdo(2→8)Kdo(2→4)Kdo-BSA by various saccharides. (○) Kdo(2→4)Kdo; (□) Kdo(2→8)-7-O-Me-Kdo; (▼)Kdo(2→8)Kdo; (●) Kdo; (■)Kdo(2→8)Kdo(2→4)Kdo; (▲)Kdo(2→4)Kdo(2→4)Kdo; (◆) Ko.
Brooks, C. L., Blackler, R. J., Sixta, G., Kosma, P., Müller-Loennies, S., Brade, L., ... & Evans, S. V. (2010). The role of CDR H3 in antibody recognition of a synthetic analog of a lipopolysaccharide antigen. Glycobiology, 20(2), 138-147.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-598 | Recombinant Anti-KDO Antibody | ELISA, WB, Neut, FuncS | IgG |
MHH-598 | Recombinant Human Anti-KDO Antibody | ELISA, WB, IP, FuncS | IgG |
PABW-155 | Mouse Anti-KDO Recombinant Antibody (clone S54-10) | ELISA | Mouse IgG1, κ |
PABW-156 | Recombinant Mouse Anti-Kdo Antibody (S73-2) | ELISA | IgG |
FAMAB-0226WJ | Mouse Anti-KDO Recombinant Antibody (clone S69-4) | ELISA, WB | Mouse IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-598-S(P) | Recombinant Anti-KDO Antibody scFv Fragment | Neut, WB, FuncS | scFv |
MHH-598-S(P) | Recombinant Human Anti-KDO Antibody scFv Fragment | FC, ELISA, FuncS | scFv |
PSBL-254 | Recombinant Mouse Anti-KDO Antibody scFv Fragment (S25-2 ) | WB, IHC, FuncS | scFv |
PSBL-621 | Mouse Anti-KDO Recombinant Antibody (clone S25-39); scFv Fragment | ELISA | Mouse scFv |
PSBC-237 | Mouse Anti-KDO Recombinant Antibody (clone S25-26); scFv Fragment | ELISA | Mouse scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
MHH-598-F(E) | Recombinant Human Anti-KDO Antibody Fab Fragment | FC, IP, FuncS | Fab |
PFBL-621 | Mouse Anti-KDO Recombinant Antibody (clone S25-39); Fab Fragment | ELISA | Mouse Fab |
PFBL-622 | Mouse Anti-KDO Recombinant Antibody (clone S64-4); Fab Fragment | ELISA | Mouse Fab |
PFBL-623 | Mouse Anti-KDO Recombinant Antibody (clone S67-27); Fab Fragment | ELISA | Mouse Fab |
PFBL-624 | Mouse Anti-KDO Recombinant Antibody (clone S73-2); Fab Fragment | ELISA | Mouse Fab |
There are currently no Customer reviews or questions for PABW-150. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.